Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK&F-89124 is a **potent and selective agonist at peripheral inhibitory prejunctional dopamine receptors (DA2 receptors)**. It is a synthetic small molecule structurally related to N,N-di-n-propyldopamine (DPDA), but with the meta-hydroxyl replaced by a cyclic amide function. It is at least an order of magnitude more potent than DPDA at DA2 receptors. Mechanistically, it inhibits norepinephrine release via DA2 receptor activation and demonstrates high selectivity for dopamine D2-like receptors with little or no activity at dopamine D1, alpha 2-adrenoceptors, or H2-histamine receptors. It has been mainly used as a research tool for studying DA2 receptor function[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SK&F-89124.